235 related articles for article (PubMed ID: 32028882)
1. Prognostic value of kallikrein-related peptidase 12 (KLK12) mRNA expression in triple-negative breast cancer patients.
Gong W; Liu Y; Preis S; Geng X; Petit-Courty A; Kiechle M; Muckenhuber A; Dreyer T; Dorn J; Courty Y; Magdolen V
Mol Med; 2020 Feb; 26(1):19. PubMed ID: 32028882
[TBL] [Abstract][Full Text] [Related]
2. Clinical relevance of the deregulated kallikrein-related peptidase 8 mRNA expression in breast cancer: a novel independent indicator of disease-free survival.
Michaelidou K; Ardavanis A; Scorilas A
Breast Cancer Res Treat; 2015 Jul; 152(2):323-36. PubMed ID: 26099606
[TBL] [Abstract][Full Text] [Related]
3. Clinical significance of human kallikrein 12 gene expression in gastric cancer.
Zhao EH; Shen ZY; Liu H; Jin X; Cao H
World J Gastroenterol; 2012 Dec; 18(45):6597-604. PubMed ID: 23236234
[TBL] [Abstract][Full Text] [Related]
4. Human kallikrein-related peptidase 12 (KLK12) splice variants expression in breast cancer and their clinical impact.
Talieri M; Devetzi M; Scorilas A; Pappa E; Tsapralis N; Missitzis I; Ardavanis A
Tumour Biol; 2012 Aug; 33(4):1075-84. PubMed ID: 22351561
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of survivin and EGFR protein expression in triple-negative breast cancer (TNBC) patients.
Zhang M; Zhang X; Zhao S; Wang Y; Di W; Zhao G; Yang M; Zhang Q
Target Oncol; 2014 Dec; 9(4):349-57. PubMed ID: 24233638
[TBL] [Abstract][Full Text] [Related]
6. Human kallikrein 5 as a novel prognostic biomarker for triple-negative breast cancer: tissue expression analysis and relationship with disease course.
Yang F; Li JY; Yin QN; Yang K; Dong SN; Bai LJ; Liu P; Tong XW
Genet Mol Res; 2015 Aug; 14(3):9655-66. PubMed ID: 26345898
[TBL] [Abstract][Full Text] [Related]
7. Gene expression in triple-negative breast cancer in relation to survival.
Wang S; Beeghly-Fadiel A; Cai Q; Cai H; Guo X; Shi L; Wu J; Ye F; Qiu Q; Zheng Y; Zheng W; Bao PP; Shu XO
Breast Cancer Res Treat; 2018 Aug; 171(1):199-207. PubMed ID: 29748761
[TBL] [Abstract][Full Text] [Related]
8.
Uzelac B; Krivokuca A; Susnjar S; Milovanovic Z; Supic G
Genet Test Mol Biomarkers; 2021 Mar; 25(3):227-235. PubMed ID: 33734898
[No Abstract] [Full Text] [Related]
9. Kallikrein-related peptidase 6 (KLK6) expression differentiates tumor subtypes and predicts clinical outcome in breast cancer patients.
Haritos C; Michaelidou K; Mavridis K; Missitzis I; Ardavanis A; Griniatsos J; Scorilas A
Clin Exp Med; 2018 May; 18(2):203-213. PubMed ID: 29435805
[TBL] [Abstract][Full Text] [Related]
10. Role of transforming growth factor-β1 in triple negative breast cancer patients.
Zhang M; Wu J; Mao K; Deng H; Yang Y; Zhou E; Liu J
Int J Surg; 2017 Sep; 45():72-76. PubMed ID: 28754615
[TBL] [Abstract][Full Text] [Related]
11. Elevated levels of both microRNA 378 (miR-378) and kallikrein-related peptidase 4 (KLK4) mRNA are associated with an unfavorable prognosis in triple-negative breast cancer.
Gong W; Zhu C; Liu Y; Muckenhuber A; Bronger H; Scorilas A; Kiechle M; Dorn J; Magdolen V; Dreyer T
Am J Transl Res; 2021; 13(3):1594-1606. PubMed ID: 33841682
[TBL] [Abstract][Full Text] [Related]
12. Elevated expression of HABP1 is a novel prognostic indicator in triple-negative breast cancers.
Wang J; Song Y; Liu T; Shi Q; Zhong Z; Wei W; Huang S; Pang D
Tumour Biol; 2015 Jun; 36(6):4793-9. PubMed ID: 25794640
[TBL] [Abstract][Full Text] [Related]
13. Kallikrein-Related Peptidase 12 (KLK12) in Breast Cancer as a Favorable Prognostic Marker.
Sato A; Takagi K; Yoshimura A; Tsukamoto W; Yamaguchi-Tanaka M; Miki Y; Ebata A; Miyashita M; Suzuki T
Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37176127
[TBL] [Abstract][Full Text] [Related]
14. Identification of tRNA-derived small noncoding RNAs as potential biomarkers for prediction of recurrence in triple-negative breast cancer.
Feng W; Li Y; Chu J; Li J; Zhang Y; Ding X; Fu Z; Li W; Huang X; Yin Y
Cancer Med; 2018 Oct; 7(10):5130-5144. PubMed ID: 30239174
[TBL] [Abstract][Full Text] [Related]
15. Human kallikrein-related peptidase 12 (KLK12) splice variants discriminate benign from cancerous breast tumors.
Papachristopoulou G; Tsapralis N; Michaelidou K; Ardavanis-Loukeris G; Griniatsos I; Scorilas A; Talieri M
Clin Biochem; 2018 Aug; 58():78-85. PubMed ID: 29807016
[TBL] [Abstract][Full Text] [Related]
16. Characterization of kallikrein-related peptidase 4 (KLK4) mRNA expression in tumor tissue of advanced high-grade serous ovarian cancer patients.
Gong W; Liu Y; Seidl C; Dreyer T; Drecoll E; Kotzsch M; Bronger H; Dorn J; Magdolen V
PLoS One; 2019; 14(2):e0212968. PubMed ID: 30811511
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of proline, glutamic acid, leucine rich protein 1 (PELP1) in triple-negative breast cancer: a retrospective study on 129 cases.
Zhang Y; Dai J; McNamara KM; Bai B; Shi M; Chan MS; Liu M; Sasano H; Wang X; Li X; Liu L; Ma Y; Cao S; Xing Y; Zhao B; Song Y; Wang L
BMC Cancer; 2015 Oct; 15():699. PubMed ID: 26472563
[TBL] [Abstract][Full Text] [Related]
18. P53 and Ki-67 as prognostic markers in triple-negative breast cancer patients.
Pan Y; Yuan Y; Liu G; Wei Y
PLoS One; 2017; 12(2):e0172324. PubMed ID: 28235003
[TBL] [Abstract][Full Text] [Related]
19. Association of p53 expression with poor prognosis in patients with triple-negative breast invasive ductal carcinoma.
Li JP; Zhang XM; Zhang Z; Zheng LH; Jindal S; Liu YJ
Medicine (Baltimore); 2019 May; 98(18):e15449. PubMed ID: 31045815
[TBL] [Abstract][Full Text] [Related]
20. A CLDN1-negative phenotype predicts poor prognosis in triple-negative breast cancer.
Ma F; Ding X; Fan Y; Ying J; Zheng S; Lu N; Xu B
PLoS One; 2014; 9(11):e112765. PubMed ID: 25393310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
